Krish Patel, MD
Long-term follow-up findings recently presented with the BTK inhibitors acalabrutinib (Calquence) and ibrutinib (Imbruvica), and updated data with the next-generation agent zanubrutinib (BGB-3111), continued to demonstrate clinical activity in patients with relapsed/refractory mantle cell lymphoma (MCL).
, Patel discussed some of the most significant MCL data presented during the 2018 ASH Annual Meeting and how the use of BTK inhibitors will evolve going forward.
OncLive: Could you discuss some of the most significant MCL abstracts presented during this year’s ASH Annual Meeting?
: The first one I thought was really interesting is in the frontline setting. There was an abstract presented from a combination of 2 phase II clinical trials that were done at Dana-Farber and Washington University in St. Louis, as well as some patients who were treated off clinical trial. In that particular abstract, what the investigators were looking at were overall responses, progression-free survival (PFS), and overall survival (OS) using an induction regimen of bendamustine/rituximab (Rituxan) given for 3 cycles. If patients were having an appropriate clinical response, they went on to get 3 cycles of rituximab/cytarabine before getting an autologous stem cell transplant.
... to read the full story